Microbiota and Network Medicine

Prof. Zh.D Semidotskaya, ass. prof.  I.O Chernyakova,  ass. prof. M.Yu. Neffa, A.E. Chernyakova

Kharkiv National Medical University

Kharkiv Regional Clinical Dispensary for Radiation Protection of the Population

The article outlines the modern understanding of the microbiota as a decentralized network structure, is in constant feedback with the hierarchical network of the host, his brain, cardiovascular, respiratory, urinary, immune systems, forming a microbiota-macrobiont network. The problems of network medicine are highlighted: the relationship between molecular, genetic origin and phenotypic manifestations of various diseases that are manifested through the construction of complex scale-free networks, the importance of social connections of different nature, the role of conscientiousness, observation, competence of the doctor who examines the patient, for the effectiveness of network analysis, the ability to highlight in the network are central nodes that are potential targets for targeted therapy. The main goal at the moment is to build a microbiotic network of human diseases, the central node of which will be the microbiota as the basis for creating a new network paradigm of diseases and their multitarget treatment.

Key Words: microbiota, network medicine, microbiota-macrobiont network, central nodes, targeted therapy.

https://dx.doi.org/10.15407/internalmed2019.02.005

Download.PDF

For citing:

  1. Семидоцкая, Ж.Д. Микробиота и сетевая медицина / Ж.Д. Семидоцкая, И.А. Чернякова, М.Ю. Неффа, А.Е. Чернякова // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2019. – № 2. – С. 5-11. doi: 10.15407/internalmed2019.02.005.
  2. Semidotskaya ZD, Chernyakova IA, Neffa MYu, Chernyakova AE. [Microbiota and Network Medicine]. Shidnoevr. z. vnutr. simejnoi med. 2019;2:5-11. doi: 10.15407/internalmed2019.02.005. Russian.

References:

1. Balabantseva AP, Tkach SM, Kliaritskaia IL. Transplantaciya fekal’noj mikrobioty kak effektivnyj metod lecheniya kishechnoj patologii, nekotoryh metabolicheskih i autoimmunnyh zabolevanij [Faecal microbiota transplantation as an effective method of treatment of enteropathy and some metabolic and autoimmune conditions]. Krymskij terapevticheskij zhurnal. 2016;1(28):12-21. Russian.

2. Velihov P. Analiz bezmasshtabnyh setej. [Internet]. 2007. Russian. Available from: http://synthesis.ipi.ac.ru/sigmod/seminar/velikhov.pdf

3. Vorobey ES, Voronkova OS, Vinnikov AI. Bakterialni bioplivky. Quorum sensing – «vidchuttia kvorumu» u bakterii v bioplivkakh [Bacterial biofilms. Bacteria quorum sensing in biofilms]. Visnyk of Dnipropetrovsk University. Biology. Ecology. 2012;20(1):13-22. Ukrainian
https://doi.org/10.15421/011202

4. Ditert R. Chelovecheskij superorganizm: Kak mikrobiom izmenil nashi predstavlenija o zdorovom obraze zhizni [The Human Superorganism: As a Microbiome change our ideas about a healthy lifestyle]. Per. s angl. Moscow (Russia): Izd. Kolibri, 2017. 416 p. Russian.

5. Drapkina OM, Shirobokikh OE. Rol’ kishechnoj mikrobioty v patogeneze serdechno-sosudistyh zabolevanij i metabolicheskogo sindroma [Role of Gut Microbiota in the Pathogenesis of Cardiovascular Diseases and Metabolic Syndrome]. Rational Pharmacotherapy in Cardiology. 2018;14(4):567-574. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-4-567-574
https://doi.org/10.20996/1819-6446-2018-14-4-567-574

6. Yevin IA, Rosin AV, Son NP, Chernyshova DI. Setevaya medicina [Network medicine]. Slozhnye sistemy. 2016;1(18):38-47. Russian
https://doi.org/10.1016/S1634-7358(16)80632-4

7. Ilyina EN, Olekhnovich EI, Pavlenko AV. Rezistom mikrobioty kishechnika kak istochnik formirovaniya lekarstvennoj ustojchivosti vozbuditelej infekcionnyh zabolevanij cheloveka [The gut microbiota resistome provides development of drug resistance in causative agents of human infectious diseases]. Patogenez. 2017;15(3):20-32. Russian.

8. Jong Je. Kak mikroby upravljajut nami. Tajnye vlastiteli zhizni na Zemle. Per. s angl.OOO Izd. AST; 2016. 352 . Russian.

9. Larin OS, Tkach SM, Tymoshenko OS, Kuzenko JuG. Modyfikacija kyshkovoji mikrobioty i fekaljna transplantacija jak perspektyvni metody likuvannja ozhyrinnja, insulinorezystentnosti i cukrovogho diabetu 2 typu [Modification of intestinal microbiota and faecal transplantation as a perspective method of treatment of obesity, insulin resistance and diabetes mellitus type 2]. Clinical Endocrinology And Endocrine Surgery. 2016;2(54):20-26. Ukrainian. doi: http://dx.doi.org/10.24026/1818-1384.2(54).2016.75861
https://doi.org/10.24026/1818-1384.2(54).2016.75861

10. Lukichev BG, Rumyantsev AS, Akimenko V. Colonic Microbiota And Chronic Kidney Disease. Message One. Nephrology (Saint-Petersburg). 2018;22(4):57-73. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-4-57-73
https://doi.org/10.24884/1561-6274-2018-22-4-57-73

11. Lukichev BG, Rumyantsev AS, Panina IY, Akimenko V. Colonic Microbiota And Chronic Kidney Diseases Intestinal Microbiota And Chronic Kidney Disease. Part II. Nephrology (Saint-Petersburg). 2019;23(1):18-31. (In Russ.) https://doi.org/10.24884/1561-6274-2018-23-1-18-31
https://doi.org/10.24884/1561-6274-2018-23-1-18-31

12. Mejer E. «Vtoroj mozg»: kak mikroby v kishechnike upravljajut nashim nastroeniem, reshenijami, zdorov’em. Per. S angl. Moskva: Izd. ANF; 2018. 348p. Russian.

13. Oleskin AV, Jel’-Registan TI, Shender BL. Mezhmikrobnye himicheskie vzaimodejstvija i dialog mikrobiota-hozjain: rol’ nejromediatorov. Mikrobiologija. 2016;1(85):3-25. Russian.
https://doi.org/10.7868/S0026365616010080

14. Fadeenko GD, Bogun LV. Disbioz kishechnika v praktike vracha-internista. Suchasna gastroenterologіja. 2013;1(69):89-96. Russian.

15. Khachaturyan NE, Egshatyan LV. [Intestinal Microbiota Modulation by Metformin] Effective Pharmacotherapy. Endocrinology.2017;4 (43). Russian.

16. Hmel’ IA, Metlickaja AZ. Quorum sensing reguljacija jekspressii genov – perspektivnaja mishen’ dlja sozdanija lekarstv protiv patogennosti bakterij Molekul. Biologija . 2006;40:195-210. Russian.

17. Shirinskiy VS, Shirinskiy IV. [Hub therapy as a new opportunity for treatment of comorbid diseases]. Sibirskij med. zhurnal. 2014;4:13-21.Russian

18. Barabasi AL, Reka A. Emergence of Scaling in random networks. Science, 1999;286:509-512. DOI:10.1007/978-3-658-21742-6_6
https://doi.org/10.1007/978-3-658-21742-6_6

19. Barabasi AL. Network Medicine – from Obesity to the “Diseasome”.Barabasi A L. N. Engl. J. Med. 2007;357:404-407. DOI:10.1056/nejme078114
https://doi.org/10.1056/NEJMe078114

20. Belisario JE, Faintuch J, Garay M. Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases. Malpartida. Mediators of Inflammation. 2018. Article D 203783812p. DOI:10.1155/2018/2037838.
https://doi.org/10.1155/2018/2037838

21. Ben-Jacob E. Bacterial survival strategies suggest rethinking cancer cooperativity. Ben-Jacob E, Coffey D S, Levine H. Trends in Microbiology. 2012; 20(9):403-410. DOI:10.1016/j.tim.2012.06.001.
https://doi.org/10.1016/j.tim.2012.06.001

22. Brackman G, Coenye T. Quorum sensing inhibitors as anti-biofilm agents. Curr. Pharm.2015; 21; 5-11. DOI:10.2174/1381612821666150310101014
https://doi.org/10.2174/1381612821666150310101014

23. Csermeley P, Agoston V, Pongor S. The efficiency of multitarget drugs: the network approach might help drug design. Trends Pharmacol Sci. 2005 Apr;26(4):178-82. DOI:10.1016/j.tips.2005.02.007.
https://doi.org/10.1016/j.tips.2005.02.007

24. Delago A, Mandabi A, Meyler MM. Natural Quorum sensing Inhibitors – Small Molecules, Big Messages. Delago A, Mandabi A, Meyler M M. Israel Journal of Chemistry.2015. DOI:10.1002/ijch.2015. 00052/
https://doi.org/10.1002/ijch.201500052

25. Dessaux Y, Chapelle E, Faure D. Quorum sensing and quorum quenching in soil ecosystem. In: G. Witzany (ed). Biocommunication in Soil Microoragnisms. Springer, 2011; 339-369. DOI:10.1007/978-3-642-14512-4_13
https://doi.org/10.1007/978-3-642-14512-4_13

26. Dickson RP, Erb- Downward JR, Marttinez FJ, Hulfnagel GB. The Microbiome and the respiratory tract. Ann. Rev. Physiol. 2016;78:481-504. DOI:10.1146/annurev-physiol-021115-105238
https://doi.org/10.1146/annurev-physiol-021115-105238

27. Fetzner S. Quorum quenching enzymes. Biothechnol.2015;201: 2-14. DOI:10.1016/j.jbiotec.2014.09.001
https://doi.org/10.1016/j.jbiotec.2014.09.001

28. Fujimura KE, Lynch SV. Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. Cell Host Microbe. 2015;17:595-602. DOI:10.1016/j.chom.2015.04.007
https://doi.org/10.1016/j.chom.2015.04.007

29. Galla S, Chakraborty BM, Vijay JB. Microbiotal- Host interaction and hypertension. Kumar. Physiology. 2017;32:224-233. DOI:10.1152/physiol.00003.2017
https://doi.org/10.1152/physiol.00003.2017

30. Garding S, Verbeke K, Vipond DT, Corfe BM, Oven LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015; Feb2; 26:26191. doi:10.3402/mehd. v.26. 26191 ecollection 2015.
https://doi.org/10.3402/mehd.v26.26191

31. Grandelement C, Tanniers M, Morena S, Dessaux Y, Faure D. Quorum quenching: role in nature and applied developments. FEMC Microbiol.Rev. 2016;40(1):86-116. DOI:10.1093/femsre/fuv038
https://doi.org/10.1093/femsre/fuv038

32. Guo N. Network Medicine: New Paradigm in the Omics – Era. Anatomy physiol. 2011;1:1: e 106. DOI:10, 4172( 2161-0940. 1000 e 106

33. Gupta SU, Allen-Vercol E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Ady Gastroenterol.2016;9(2):229-239. DOI:10.1177/1756283×15607414
https://doi.org/10.1177/1756283X15607414

34. Hidalgo CA, Bluimm N, Barabasi AL, Christakis NA dynamic network approach for the study of humans phenotypes. PLos. Comput. Biol.2009;5e 1000353. DOI:10.1371/journal.pcbi.1000353
https://doi.org/10.1371/journal.pcbi.1000353

35. Jamai M, Ahmad W, Andbeb S, Jalil F, Imran M, Navaz M, Cussian T Y, Ali M, Rafiq M, Kamil MA. J Bacterial Biofilm and associated infections. Clin.Med.Assoc.2018;81(1):7-11. DOI:10.1016/j.jcma.2017.07.012
https://doi.org/10.1016/j.jcma.2017.07.012

36 Li L, Alderson D, Tanaka R, Doyle J C, Willinger W. Towards a Theory of Scale – Free Graphs: Definition, Properties, and Implications (Exten ded Version). . Internet Mathematics. 2005. DOI:10.1080/15427951.2005.10129111
https://doi.org/10.1080/15427951.2005.10129111

37. Martinez J L. General prinziplez of antibiotic resistance in bacteria. Drug Discavery Today: Technologist. 2014;11:33-39. DOI:10.1016/j.ddtec.2014.02.001
https://doi.org/10.1016/j.ddtec.2014.02.001

38. Marx P, Anfal P, Bolgar B, Badgy G, Deakin D, Juhazz G. Comorbidities in the diseasome are more apparent than real what Bayesian filtering reveals about the comorbidities of depression. PLoS Comut Biol.2017;13(6): e 1005487. DOI:10.1371/journal.pcbi.1005487
https://doi.org/10.1371/journal.pcbi.1005487

39. Norris V, Molina F, Gewitz A T. J. Hypothesis: bacteria control host appetites. Bacteriol; 2013;195: 411-416. DOI:10.1128/jb.01384-12
https://doi.org/10.1128/JB.01384-12

40. Oleskin AV. Network structures biological systems. Biol. Bull.Rev; 2014;74(1):47-70. DOI:10.1134/s2079086414010034
https://doi.org/10.1134/S2079086414010034

41. Perry JA, Westman EL, Wright GD. The antibiotic resistome: What’s new? Curr.Opin. Microbiol. 21:45-50. DOI:10.1016/j.mib.2014.09.002
https://doi.org/10.1016/j.mib.2014.09.002

42. Remeli M, Stephanska B, Lovretic L. Nutriepigenomics the role of nutrition in epigenetic control of human diseases. Curr. Opin. Clin. Nutr. Metab. Care. 2015;18(4):28-333. DOI:10.1097/00075197-199803000-00016
https://doi.org/10.1097/00075197-199803000-00016

43. Remy B, Mion S, Pluer L, Elias M, Chabriere E, Daude D.Interference in Bacterial Quorum Sensing: A Biopharmaceutical Perspective Front. Pharmacol. 2.-9:203. DOI:103389/fpharm. 2018/ 00203
https://doi.org/10.3389/fphar.2018.00203

44. Santisteban MM, Kim S, Pepine CJ, Razada MK. Brain-gut-bone marrow axis: implications for hypertension fnd related therapeutics. Circ. Res. 2016;118:1327-1336. DOI:10.1161/circresaha.116.307709
https://doi.org/10.1161/CIRCRESAHA.116.307709

45. Smith M, Kelly C, Alm E. How to regulate faecal transplants. Nature.2014;606:290-291. DOI:10.1038/506290a
https://doi.org/10.1038/506290a

46. Sontheimer E J. The Bacterial Origins of the CRISPR GenomeEdition Revolution. Sontheimer E J, Barrangon R. Human Gene Therapy. 2015;26(7):413 – 424. DOI:10.1089/hum.2015.091
https://doi.org/10.1089/hum.2015.091

47. Stilling RM, Bordenstein SR, Dinan TG, Cryan JF. Friends with social benefits: host-microbe interaction as a driver of brain evolution and development. Front. Cell. infect. Microbiol.; 2014; 4. Doi: 103389/ fsimb. 2014. 00147
https://doi.org/10.3389/fcimb.2014.00147

48. Tang WH, Kitai T, Hazen SL Gut microbiota in cardiovascular disease. Circ. Res. 2017;120(7):1183 – 1196. DOI:10.1161/circresaha.117.309715
https://doi.org/10.1161/CIRCRESAHA.117.309715

49. Thompson CM, Marsden AE, Tischler AH, Koo J, Visick KL. Vibrio fischeri Biofilm Formation Prevented by a Trio of Regulators. Appl. Environ Microbiol. 2018;84(19). e01257-18. DOI:10.1128/aem.01257-18
https://doi.org/10.1128/AEM.01257-18

50. Vila J. Microbiota transplantation and /or CRISPR / CAS in the battle against antimicrobial resistance. Clin. Microbiol. And Inf. 2018;24(7):684-688. DOI:10.1016/j.cmi.2018.03.043
https://doi.org/10.1016/j.cmi.2018.03.043

51. Wing MC, Patel SS, Ramesani A, Rai DS. Gut microbiome in chronic kidney disease. Exp. Physiol. 2016;101:477-479. DOI:10.1113/ep085283
https://doi.org/10.1113/EP085283

52. Yildrim M, Goh K, Gusik M, Barabasi A L, Vidali M Drug – target network. Nature biotechnology. 2007;25(10). DOI:10.1038/nbt1338
https://doi.org/10.1038/nbt1338

53. Zhou X, Menche J, Barabási AL, Sharma A. Human symptoms-disease network. Nat Commun. 2014 Jun 26;5:4212. doi: 10.1038/ncomms5212. PubMed PMID: 24967666.
https://doi.org/10.1038/ncomms5212